Osteoporosis InternationalFerrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (deno- sumab) affect inflammation and immunity? Osteoporos Int 22:435-446FERRARI-LACRAZ S,FERRARI S.Do RANKL inhibitors (denosumab
英文摘要 One of the major challenges for discovering protein-protein interaction inhibitors is identifying selective and druggable binding sites at the protein surface. Here, we report an approach to identify a small molecular ...
Hattori K, et al. Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study[J]. Nagoya J Med Sci. 2019;81(4):571-585. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (...
Rationale for RANKL inhibitors to treat osteoporosis Receptor activator of nuclear factor-κB (RANK) is a member of the tumor necrosis factor family expressed by osteoclasts and their precursors [29]. The interaction of RANK with its ligand (RANKL) has been identified as the final common pathway...
Taken together, all of the available data suggest that inhibitors of the biological activity of RANKL hold promise as therapeutic agents for a wide variety of conditions in which bone remodeling is dysregulated, including postmenopausal osteoporosis and cancer-induced bone diseases. In a proof-of-prin...
All authors declare no competing interests except for M.B.J. who holds two patents on the use of RANKL inhibitors to treat male infertility. R.B. has been on the advisory Board of Amgen and B.L. is now employed by Radius Health. All other authors state no conflicts of interest. ...
The new RANKL inhibitor has shown promising results in treating osteoporosis. (这种新的RANKL抑制剂在治疗骨质疏松症方面显示出了良好的前景。) Researchers are developing more effective RANKL inhibitors to prevent bone loss. (研究人员正在开发更有效的RANKL抑制剂以防止骨丢失。) The use of RANKL inhibitors...
A small molecule that can selectively inhibit sRANKL-RANK interactions is a therapeutic solution for treating osteoporosis avoiding immune side-effects. Until now, small molecular sRANKL-selective PPIs inhibitor is not discovered yet. The major premise of discovering such small molecular inhibitors is ...
and as a sole medication to avoid the potential for drug interactions with other agents. In the event these studies show arrest of the osteolysis with improvement in the osteoporosis, this would provide strong support for the dominance of the RANKL driven osteoporosis in the genesis of the osteo...
【Abstract】Osteoporosis has become an important public problem endangering national health, and the mortality caused by osteoporosis and its complications has ranked fourth. The main reason for osteoporosis is that the balance between bone formation and bone absorption is broken. Nuclear factor receptor...